CombiMatrix (CBMX) Skyrockets on Contract, Oncolytics (ONCY)

New Post Public Reply Private Reply Replies (0) Message Board
riddock57

http://pennyomega.com/img/cbmx1.jpg CombiMatrix Corporation (Nasdaq:CBMX)

Shares of CBMX soared on Thursday's trading session after the company reported that it has entered into a contractual agreement with America's Choice Provider Network(R) (ACPN(R)) for coverage of its diagnostic laboratory services.

The agreement with ACPN, a San Diego-based national healthcare savings provider network, provides access to CBMX 's suite of molecular diagnostic solutions and comprehensive clinical support—specializing in prenatal, miscarriage and pediatric healthcare—to more than 14 million members.

http://pennyomega.com/img/cbmx_chart4.png

CBMX provides valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care — specializing in miscarriage analysis, prenatal and pediatric healthcare. CBMX offers comprehensive testing services for the detection of genetic abnormalities at the DNA level, beyond what can be identified through traditional methodologies.

More about CombiMatrix Corporation (Nasdaq:CBMX) at www.combimatrix.com

**

http://pennyomega.com/img/oncy.jpg Oncolytics Biotech Inc. (Nasdaq:ONCY)

ONCY reported positive top-line data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018).

Overall, the treatment combination was found to be safe and well tolerated by patients.

ONCY 's REOLYSIN is a proprietary variant of the reovirus, an acronym for Respiratory Enteric Orphan Virus, which is widely found in the environment. By adulthood, most people have been exposed to the reovirus. The reovirus is non-pathogenic, which means that infections are typically asymptomatic.

Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. Head and neck cancers can also begin in the salivary glands, but salivary gland cancers are relatively uncommon. Salivary glands contain many different types of cells that can become cancerous, so there are many different types of salivary gland cancer.

http://pennyomega.com/img/head-_and-_neck_cancer1.jpg

Alcohol and tobacco use (including smokeless tobacco, sometimes called “chewing tobacco” or “snuff”) are the two most important risk factors for head and neck cancers, especially cancers of the oral cavity, oropharynx, hypopharynx, and larynx. At least 75% of head and neck cancers are caused by tobacco and alcohol use. People who use both tobacco and alcohol are at greater risk of developing these cancers than people who use either tobacco or alcohol alone. Tobacco and alcohol use are not risk factors for salivary gland cancers.

Head and neck cancers account for approximately 3% of all cancers in the United States. These cancers are nearly twice as common among men as they are among women. Head and neck cancers are also diagnosed more often among people over age 50 than they are among younger people. (Source: National Cancer Institute)

To learn more about head and neck cancers, go to www.cancer.gov/cancertopics/factsheet/Sites-Types/head-and-neck

According to ONCY , the trial results demonstrate that REOLYSIN can be safely added to this chemotherapeutic combination (carboplatin and paclitaxel ).

ONCY believes that the addition of REOLYSIN to other regimens will not increase the frequency or severity of adverse events caused by the chemotherapeutic agents with which it is combined.

http://pennyomega.com/img/oncy_chart21.png

ONCY is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

More about Oncolytics Biotech Inc. (Nasdaq:ONCY) at www.oncolyticsbiotech.com .

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

According to eMarketer, online retail sales will grow from $225.5 billion in 2012, to $434.2 billion in 2017.

U.S. companies and government agencies will purchase $559 billion via the web in 2013, Forrester Research Inc. predicted in its first estimate of the b2b e-commerce market released last year.

Looking to deliver value for its stockholders in both the near and long term, CRWE is refocusing its strategic plan to improve the potential future growth for the company, targeting the multi-billion dollar online video-sharing and online b2b markets, with its Division CRWETube ( www.crwetube.com ) and its iB2B Global project, respectively.

http://pennyomega.com/img/crwenov21.png

As a worldwide online multi-media publisher, CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. CRWE launches, invests and manages select businesses, projects and real estate endeavors.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

CombiMatrix Corp (CBMX) Stock Research Links

CBMX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocuphire Pharma Faces Scrutiny Over Shareholder Obligations

Updated Category News Views 81

Ocuphire Pharma Under Investigation by Ademi LLP Recently, there have been growing concerns regarding the fiduciary responsibilities of Ocuphire Pharma, Inc. (NASDAQ: OCUP) to its public shareholders. Ademi LLP has initiated an investigation focused on whether the company is adequately protecting the interests of its shareholders amidst its dealings with Opus Genetics....

Continue Reading
Investigation Into Shareholder Claims Against AMLX, FIVE, HUM, and VSTS

Updated Category News Views 190

Grabar Law Office Investigates Shareholders' Rights Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), Five Below, Inc. (NASDAQ: FIVE), Humana Inc. (NYSE: HUM), and Vestis Corp. (NYSE: VSTS) shareholders may have claims worth exploring. Grabar Law Office wants to inform these shareholders about the ongoing investigations into potential securities fraud that could have affected...

Continue Reading
Investors Seek Recovery in Class Action Against Paragon 28, Inc.

Updated Category News Views 109

Class Action Lawsuit Filed for Paragon 28, Inc. Investors We are reaching out to inform investors about an important class action securities lawsuit involving Paragon 28, Inc. This initiative aims to recover losses for investors who may have been adversely affected by purported securities fraud associated with the company. Details of the Class Action The class action...

Continue Reading
Alto Ingredients, Inc. Announcement for Q2 2025 Results

Updated Category News Views 165

Alto Ingredients, Inc. to Announce Second Quarter Financial Results Alto Ingredients, Inc. (NASDAQ: ALTO), a prominent producer and distributor of specialty alcohols and renewable fuels, is set to release its financial results for the second quarter of 2025. This announcement will take place after the market closes on Wednesday, August 6, 2025. Conference Call Details...

Continue Reading
Phare Bio Secures $27 Million to Revolutionize Antibiotic Discovery

Updated Category News Views 226

Phare Bio scored big back in 2024 with up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). This isn’t just pocket change; it’s a lifeline aimed at supercharging their generative artificial intelligence (AI) platform. Teaming up with MIT's Collins Lab and Harvard's Wyss Institute, they set their sights on developing new classes...

Continue Reading